Barinthus Biotherapeutics Plc (BRNS) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Barinthus Biotherapeutics Plc  (NASDAQ: BRNS)

Barinthus Biotherapeutics Plc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Barinthus Biotherapeutics Plc in the second quarter 2026?
Barinthus Biotherapeutics Plc recorded a cumulative net loss of $-42 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -59.2%.

Within the Major Pharmaceutical Preparations industry 190 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 3048 to 3329.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change -44.25 % -42.49 % -42.91 % -46.97 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -42 -52 -66 -76 -70
Return On Equity (TTM) -59.2 % -63.86 % -70.53 % -70.2 % -54.76 %
BRNS's Total Ranking # 3329 # 3048 # 2547 # 3000 # 2762
Equity (TTM) in Millions 57 66 74 85 102
Seq. Equity Change -14.06 % -10.52 % -12.14 % -17.49 % -11.34 %
Seq. Net Income Change - - - - -

Back to BRNS Management Effectiveness >> BRNS's 5 Years Annual ROE >> Compare BRNS ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 191
Sector # 449
Overall # 3329

Return On Equity Statistics
High Average Low
4.5 %
-34.11 %
-70.53 %
(Sep 30 2022)   (Dec 31 2025)



  News about Barinthus Biotherapeutics Plc Return on Equity ROE

Barinthus Biotherapeutics Shifts Strategic Focus to Immunology and Inflammation Amidst Financial Challenges and Leadership Change,

Strategic Shift and Financial Challenges: Barinthus Bio s Journey in Immunology and InflammationIn the rapidly evolving landscape of biopharmaceuticals, Barinthus Biotherapeutics plc, based in Oxford, UK, has recently communicated a significant strategic pivot towards immunology and inflammation (IandI). This decision comes at a time when the company is navigating a challenging financial terrain, marked by considerable net losses and a precarious return on equity. This article delves into Barinthus Bio s current standing, strategic focus, and financial outlook, particularly as it endeavors to innovate in the crucial fields of immunology and inflammation. A Focus on ImmunotherapyBarinthus Biotherapeutics is a clinical-stage company committed to developing innovative immunotherapeutic candidates that aim to harness the power of T cells in disease management. This approach distinguishes Barinthus in a crowded market. The company’s strategic decision to concentrate efforts in the IandI arena reveals an understanding of the burgeoning demand for effective therapies in these domains, especially in the face of unresolved health crises and ongoing global health challenges.

Barinthus Bios New CSO, Geoffrey Lynn, Faces Uphill Battle: Can Breakthroughs in Hepatitis B Resuscitate a Biotech Struggling with Losses,

Barinthus Biotherapeutics Promotes Lynn Amid Financial Struggles: A Potential Rebirth in Hepatitis B Treatment?An Look into Barinthus Biotherapeutics and the Future of Hepatitis B TreatmentIn a surprising turn of events, Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company headquartered in Oxford, UK, has recently announced the promotion of Geoffrey Lynn, M.D. Ph.D. to the position of Chief Scientific Officer (CSO) effective December 1, 2024. Dr. Lynn, a co-inventor of the company s SNAP-TI technology, takes over from Nadge Pelletier, Ph.D. who has resigned amidst rumors of pursuing alternative opportunities closer to home. This leadership change occurs at a critical juncture for Barinthus, as it grapples with financial losses and aims to reinforce its position in the competitive biopharmaceutical landscape.The announcement comes on the heels of a troubling report that revealed Barinthus Biotherapeutics recorded a cumulative net loss of $56 million during the 12 months ending in the second quarter of 2024. The company’s return on equity (ROE) stands at a concerning negative 30.7%, raising questions about its sustainability and long-term strategy in a demanding industry. Despite these challenges, within the Major Pharmaceutical Preparations sector, Barinthus achieved the highest return on equity, which suggests an intriguing dynamic at play—excellence in innovation coupled with financial turbulence.



BRNS Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 74 130 187 243 253
Y / Y Equity Change -42.91 % -30.41 % -23.11 % -3.71 % -
Net Income in Millions -66 -61 -73 5 -51
Y / Y Net Income Change - - - - -
Return On Equity -89.46 % -47.02 % -39.28 % 2.19 % -20.24 %

Back to BRNS Management Effectiveness >> BRNS's 5 Years Annual ROE >> Compare BRNS ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
BRNS's' Return on Equity at Yahoo Finance
BRNS's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for BRNS's Competitors
Subscribers only: Roe for Barinthus Biotherapeutics Plc's Suppliers
Subscribers only: Return On Equity for BRNS's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE

Date modified: 2026-09-26T07:39:49+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.